To All Medical Laboratory Users:

This edition of the Lab Med Update has the following articles:

MEDICAL LABORATORIES

SEPTEMBER 2021

Lupus Anticoagulant Panel

DOAC (direct oral anticoagulant) Removal

The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot-based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with antiphospholipid syndrome (APS), a common cause of acquired thrombotic disease.

Beginning in September, the provider will be prompted to answer two questions when ordering the Lupus Anticoagulant Panel.

Is the patient taking a Direct Oral Anticoagulant? "Yes" or "No"

If "Yes", the DOAC must be selected to complete the order.

If the patient is taking a DOAC, the specimen will be treated with a removal agent prior to running the Lupus Anticoagulant Panel.



IF YOU HAVE AN ARTICLE(S) YOU WOULD LIKE TO SHARE CONTACT:

Terri Workman Proffitt
434-924-5198

EMAIL:
Twp3q@virginia.edu

Factor VIII Assay for Hemlibra, Afstyla, Jivi

Test code: 1230400389 Synonym: F8CHROM Orderable procedures: FACTOR VIII ASSAY FOR HEMLIBRA, AFSTYLA, JIVI [LAB6449]

Beginning in September 2021, the Special Coagulation lab will offer the Chromogenic Factor VIII assay specific for monitoring the following treatments for Hemophilia A patients. **LAB6449**

Hemlibra (emicizumab)

Afstyla (antihemophilic factor (recombinant), single chain)

Jivi (antihemophilic factor (recombinant), PEGylated-aucl)

Specimen stability: 2 hours at room temperature, 3 months at -70 °C .

Normal range: 43-159 %

Reportable range: 1-200 %

Welcome Nicholas Larkey

Dr. Larkey joined UVA's Department of Pathology in July 2021 and began his new role amount the faculty directors of Clinical Chemistry, along with Director of Point of Care and Director of Davis Lab Immunology. He holds a PhD in analytical chemistry from Oregon State University and recently completed his Clinical Chemistry Fellowship at the Mayo Clinic. Prior to his fellowship at Mayo, he was a post-doctoral fellow at the University of Kansas Cancer Center where he worked on developing microfluidic platforms to monitor remission of B-ALL. We are excited that he will be sharing his wealth of knowledge with us and will be working to support the clinical laboratory testing needs within the UVA Health System.

Welcome Dr. Larkey!

Send Outs

New test kit-Helicobacter pylori BreathTest: LAB572

Mayo Clinic Laboratories will be transitioning to a new supplier, Meridian Bioscience, for our *Helicobacter pylori* Breath Test kit. This transition will allow pediatric testing for patients ages 3-17 without requiring Pediatric UHR calculation.

Expected implementation date for the new kit will be November 2nd, 2021.

The Send out laboratory will be ordering the new kits when they become available October 15th to have an inventory available for the go-live date on November 2nd

Meridian BreathID® collection kits should not be used until the go live date. **Kits received prior to go live will be rejected.**

Mayo will test UBT orders using the current collection kit for 5 days following the Meridian BreathID go –live date. After **5 days** specimens collected in the old kits will be **rejected.**

Please take appropriate steps to ensure that current collection kits are consumed or removed from inventory and that adequate Meridian BreathID® collection kits are available in your area **prior to November 2, 2021.**
The new kits will be available in the laboratory after October 15th (call 924-5227) but they cannot be used until November 2nd.

Please call the Send-Out lab at 982-4051 with any questions you may have.

Nephrocheck assay for Acute Kidney Injury (AKI)

(LAB6151)

Methylene Blue interferes with the Nephrocheck Assay. If interference is noted, the sample will be cancelled and need to be recollected.